## Abstract ## BACKGROUND: Approximately 50% of all patients with primary central nervous system lymphoma (PCNSL) are aged ≥65 years; however, this group is relatively understudied, and to the authors's knowledge, optimal treatment for older patients is not well defined. ## METHODS: This was a r
Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series
✍ Scribed by Sawyna Provencher; Céline Ferlay; Khaoula Alaoui-Slimani; Alain Devidas; Stephane Lepretre; Bernard de Prijck; Catherine Sebban; Arnaud de la Fouchardiere; Catherine Chassagne-Clement; Nicolas Ketterer; Antoine Thyss; André Delannoy; Hervé Tilly; Pierre Biron; Jean-Yves Blay; Hervé Ghesquières
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 196 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0278-0232
- DOI
- 10.1002/hon.944
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
There is very limited data on isolated systemic relapses of primary central nervous system lymphomas (PCNSL). We retrospectively reviewed the clinical characteristics and outcome of 10 patients with isolated systemic disease among 209 patients with PCNSL mainly treated with methotrexate‐based chemotherapy (CT) with or without radiation therapy (RT). Isolated systemic relapse remained rare (4.8%, 10/209 patients). Median time from initial diagnosis to relapse was 33 months (range, 3–94). Sites of relapse were mostly extranodal. Three patients presented with early extra‐cerebral (EC) relapse 3, 5 and 8 months from the beginning of initial treatment, respectively, and 7 patients had later relapses (range, 17–94 months). Treatment at relapse included surgery alone, RT alone, CT with or without radiotherapy, or CT with autologous stem cell transplantation (ASCT). Median overall survival (OS) after relapse was 15.5 months (range, 5.8–24.5) compared to 4.6 months (range, 3.6–6.5) for patients with central nervous system (CNS) relapse (p = 0.35). In conclusion, isolated systemic relapses exist but are infrequent. Early EC relapse suggests the presence of systemic disease undetectable by conventional evaluation at initial diagnosis. Patient follow‐up must be prolonged because systemic relapse can occur as late as 10 years after initial diagnosis. Whether EC relapses of PCNSL have a better prognosis than CNS relapses needs to be assessed in a larger cohort. Copyright © 2010 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND. The incidence of primary central nervous system lymphoma (PCNSL) appears to be increasing in some countries, whereas it is stable in others. Many reports the last decades have suggested that there have been improvements in the treatment of PCNSL. The objective of this st